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Abstract 
The health care system in the United States has been described as having a deficit in care for 
women during pregnancy (IOM, 2019), and as a result there has been a resurgence over the last 
decade in diseases like pertussis, which is a severe respiratory infection that is particularly 
dangerous for infants less than 3 months of age (Tan & Gerbie, 2013). The primary objective of 
this project was to implement a Tdap vaccination program and increase the rates of Tdap 
vaccinations of obstetrical patients at a San Antonio clinic. The intervention included (a) 
establishing standing orders for the Tdap vaccination, (b) encouraging physician 
recommendation of the vaccination to every pregnant patient (with each pregnancy), and (c) 
providing educational materials on the safety and benefits of the Tdap vaccination. Between Feb. 
3, 2020 and May 3, 2020, the clinic provided care to 338 obstetrical patients. All received a 
physician recommendation for the Tdap vaccination and were given further educational 
information at their initial prenatal appointment. Two-hundred and seven patients (59.2%) were 
eligible for vaccination (27-36 weeks’ gestation) and received Tdap recommendations prior to 
vaccination (mean gestational age was 29 weeks). Ten women (5%) declined the Tdap vaccine 
after recommendation. Establishing an evidence-based process for Tdap vaccination ensured 
100% of eligible patients were given recommendations and were offered the vaccination between 
27 to 36 weeks of pregnancy. Ultimately, the combination of implementing standing orders 
within the host health center, securing a physician recommendation, and increasing patient and 
staff education influenced an increase in the Tdap vaccination in obstetrical patients.  
Keywords: pregnant women, Tdap vaccinations, pertussis, passive immunity, whooping 
cough, immunization, maternal vaccination  
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A System Intervention of Tetanus, Diphtheria, and Pertussis 
Vaccination for Pregnant Women in Primary Care
In the middle of December 2019, a school in Houston, Texas, made the decision to close 
early for the winter break due to an outbreak of pertussis among its students and staff, despite the 
school’s 100% vaccination policy (Ackerman, 2019). Even with high vaccination rates, Houston 
saw 30 cases of pertussis in 2019, including those affected at this school (Ackerman, 2019). 
Unfortunately, the trend of increasing pertussis rates is not isolated to Texas. 
Pertussis, a severe acute respiratory infection that can lead to admission into an intensive 
care unit or even loss of life, particularly for infants less than 3 months of age, has seen a 
resurgence in the US in the past decade (Tan & Gerbie, 2013), despite it being largely 
preventable with the Tdap vaccination administered during pregnancy (Halperin et al., 2018). 
One study researching the presence of pertussis-related antibodies in pregnant women indicated 
that approximately 30-90% of reproductive age women have low-to-undetectable pertussis 
antibodies (Gonik et al., 2005). This creates a problem as infants are not only protected from the 
infection by the mother’s own immunity while in utero, but this immunity can cover the infant 
until 2 months of age, or until they obtain their series of diphtheria, tetanus, and pertussis
(DTap) vaccinations (Payakachat et al., 2015). Without a pertussis vaccination during pregnancy, 
an infant’s pertussis antibodies are substantially decreased by 6 weeks of age and are almost 
undetectable at 4 months (Baxter et al., 2017).  
In the search for solutions to the spread of pertussis and similar infections, agencies like 
the Centers for Disease Control (CDC) and the Prevention Advisory Committee on 
Immunization Practices recommended in 2011 that all pregnant women, as early as 20 weeks, 
should receive the Tdap vaccine (Baxter et al., 2017). In 2013, they further extended this 
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recommendation to advise the Tdap vaccine be given with each pregnancy, regardless of a 
previous Tdap vaccination (CDC, 2012). Due to concerns regarding the lack of vaccinations in 
reproductive women, as well as inequality within health care, the American College of 
Obstetricians and Gynecologists (ACOG) developed guidelines that recommended the 
administration of the Tdap vaccination between 27 and 36 weeks of gestation for all pregnant 
women, and vaccinations be included of close family members that may be in contact with a 
newborn (ACOG, 2017). An additional recommendation advises all pregnant women receive 
educational materials regarding the importance of the vaccine during pregnancy for both 
maternal and infant health (CDC, 2019).  
The health care system in the United States has been described as having a deficit in care 
for women during pregnancy (IOM, 2019). Certainly, improving and encouraging vaccination 
coverage in pregnant women could significantly reduce the disease burden, as well as improve 
the standard of care for pregnant women and increase infant immunity.  
Statement of the Problem 
The American College of Obstetrics and Gynecology recommends that every pregnant 
woman receives all required vaccinations between 27 and 36 weeks gestation, including the
Tdap vaccination (ACOG, 2017). However, in a 2017 Internet panel survey, 15.3% of recently
pregnant women reported never receiving a Tdap vaccination (Kahn et al., 2018). These 
vaccinations create immunity and protection for infants until they are old enough to be 
vaccinated themselves by stimulating maternal anti-pertussis antibodies, which are transported 
from the mother to the infant via the placenta. Ideally, these vaccinations protect pregnant 
women from pertussis near the time of delivery, prevent the mother from transferring any 
infections to the newborn, and provide protection to the newborn from pertussis in the first few 
months of life (CDC, 2013). Pregnant women rely on the obstetrician to provide the necessary 
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continuity of care and to educate them on the relevant standards and guidelines so that they can 
make informed decisions regarding vaccinations. However, the reality is that not all pregnant 
women even receive a recommendation for the Tdap vaccination, despite the fact that women are 
more likely to receive the vaccination when it is recommended or offered by a doctor or other 
medical professional (CDC, 2018). Admittedly, there are multiple contributing factors to low 
Tdap immunization rates, requiring a multi-pronged approach.  
Current Practice Assessment  
Primary System Assessment 
The host health system is a group of 15 federally qualified health centers, providing a 
variety of health care services in rural and underserved urban communities of Bexar, Kendall, 
and Hays counties in south-central Texas (Communicare Health Centers [CHC], 2019). The 
services offered include family medicine (primary care), dental care, pediatric care, women’s 
health, senior care, behavioral health, a WIC program, vision care, integrated pediatrics, 
rheumatology, hepatitis care, sports medicine, minor surgery, and general surgery (CHC, 2019). 
 A practice assessment was performed within an OB/GYN practice, at Clinic P. Clinic P is 
located on the far west side of San Antonio, Texas, in a growing area of Bexar County in need of 
OB/GYN services. Clinic P’s geographical location is a vital part of its accessibility to the public 
since it is on a major connection road between two of the city’s busiest freeways. The area is 
newly developing, with many local and small businesses, including restaurants and shopping 
centers, a high school and a community college campus, a hospital, and two major grocery 
stores. The housing available in this area also varies, ranging from single-to-multi-family houses, 
apartments, and townhomes.  
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With the growing number of families in this developing area, the clinic’s focus on 
providing family services reflects its mission of improving the health care of its surrounding 
community. Clinic P strives to serve women of childbearing age, including those who are 
uninsured and those who are insured with either private or public health insurance providers. The 
corporation's mission to help the underserved and uninsured with quality health care is a 
challenging, but worthwhile pursuit for improving and expanding the health of the population it 
serves (DeMarco, 2015). Both the clinic and the corporation’s focus on family health is 
particularly important given that the mortality rates for Bexar County in 2015 were 6.3 deaths 
per 1,000 live births, an increase from the previous year (Texas Department of State Health 
Services, 2018).  
In terms of demographics, the community surrounding the clinic is predominantly 
Hispanic, making up 67.4% and 61.7% of the population within the two zip codes that this 
FQHC serves (U.S. Census Bureau, 2017). Accordingly, both clinical staff and providers are 
fluently bilingual in both Spanish and English, which encourages a stronger community rapport, 
which in turn improves patient outcomes (Batalova & Zong, 2016).  
The clinic’s daily operations are carried out by a team of health care professionals who 
are on duty between the operating hours of 8:00 a.m. and 5:00 p.m., Monday through Friday; the 
clinic’s sonographer and lab personnel have different service hours. The team of professionals 
includes two OB/GYN physicians, four medical assistants, one licensed vocational nurse who is 
employed to serve as the supervising nurse for both the pediatric and OB/GYN clinics, a practice 
manager who is also a registered nurse, and two additional front desk personnel. The practice 
manager describes the health care providers and staff at Clinic P as a cohesive team, with the 
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only identified staffing conflict being an issue with sharing one LVN position between both the 
pediatric and OB/GYN clinics.  
The OB/GYN clinic consistently has availability for taking on new patients along with 
their existing patients. The patient visit history for the past year shows that 87.1% of the clinic’s 
patients fall between 19 and 45 years of age, with the youngest patient being 11 and the oldest 
being 86. The majority of the clinic’s patients are Hispanic, though the overall patient statistics 
reflect an ethnically diverse population. Reflecting its mission to bring health care to 
underserved populations, the clinic accepts all insurances in addition to accepting patients 
without insurance, providing an additional sliding-scale and income-based payment plan for 
patients who apply and qualify. Regarding the clinic’s family services, they provide free 
pregnancy testing and vaccinations without a physician appointment, as well as obstetrical 
services from the point of pregnancy identification until birth. The clinic also has on-site WIC 
service representatives, which patients can access before or after an appointment. These services 
and considerations maximize the patient’s ability to utilize qualifying programs that promote 
family development and increase health care outcomes.  
Based on initial observations, the microsystem assessment, and a stated desire of the 
OB/GYN providers and host health system administrators, the focus of the intervention was the 
implementation of ACOG and CDC guidelines for the administration of the Tdap vaccine to all 
pregnant patients with each pregnancy. A secondary needs assessment follows to obtain baseline 
data and assess the organization’s readiness for change.  
Secondary Needs Assessment 
The clinic’s immunization tracking system provided a baseline, pre-intervention dataset. 
The retrospective electronic medical records (EMR) review found that only 133 of 330 (40%) 
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obstetrical (OB) patients were vaccinated with the Tdap vaccination in the past year. The low 
percentage rate of Tdap vaccination for this clinic is of great concern and prompted the primary 
aim of this project: to increase the clinic’s Tdap vaccination by 50%, for a goal of 90% 
vaccination rate.  
 There are, however, significant systemic barriers to this goal. One primary barrier is the 
initial identification of a patient’s need for a Tdap vaccination and the lack of a protocol to guide 
this process. The ACOG recommends that the Tdap vaccination be administered to each obstetric 
patient for each one of their pregnancies, but the clinic’s EMR software does not currently flag 
the Tdap vaccine as an item of high importance. In comparison, there is a flag for the influenza 
vaccine in each patient’s record. The development and subsequent implementation of a protocol 
is further hindered by a general lack of knowledge related to specific elements of the ACOG 
guidelines, as well as a disregard for the underlying research supporting the recommended 
vaccination timeline which ensures the highest level of antibodies for both the mother and 
unborn infant.  
 Contributing factors to the low Tdap immunization rate in Clinic P are similar to those 
facing other OB/GYN clinics, including issues related to the educational level and occupational 
status of the mother. The CDC study conducted by Kahn et al. (2018) found that among those 
surveyed, women with the lowest Tdap vaccination coverage during pregnancy were those with 
some college education (40.7%), while women with more than an undergraduate college degree 
had the highest coverage at 61.5%. Patients of various educational levels will analyze the 
information presented to them differently, and at Clinic P, there is currently no emphasis on 
patient education related to the importance of the Tdap vaccination during pregnancy, let alone 
any educational materials that target various patient educational levels. Clinicians, medical and 
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management staff all have a responsibility to improve the medical knowledge of patients, as the 
patients learn to navigate their own health care. Vaccination education empowers women to 
make informed decisions regarding disease prevention and allows for appropriate planning 
regarding their family’s health care. In an era with an increasing anti-vaccine sentiment (Furuta 
et al., 2017), improving patient’s education regarding vaccinations is of great importance for the 
general health of not only individuals, but for the greater community as well.  
There were many project facilitators, including nurses, clinic managers, medical 
assistants, physicians, and information technology professionals. Approval for this project was 
determined by the chief medical officer, practice manager, IT supervisor, and the Health 
Insurance Portability and Accountability Act compliance officer. 
The healthcare professionals in clinic P are engaged and enthusiastic about the planned 
intervention. There are project champions in both the DNP-student mentor and the DNP student. 
The OB/GYN providers recognize the need for the intervention and agree with the focused 
elements. They further recognize that efforts focused on the National Academy of Medicine 
(formally the Institute of Medicine) aims of providing patient-centered care also require thorough 
self-assessment and intervention for issues that impede quality healthcare delivery. With 
interventions that promote positive change, the clinic can empower patients to be active 
participants in both their own and their child’s health outcomes.  
Project Identification 
The entire health care team assisted with the identification of Tdap vaccination strategies 
that would enhance the clinic's primary prevention methods aimed at decreasing the prevalence 
of infants affected by pertussis. The identified project objectives focused on improving the 
process of Tdap immunization administration in obstetric patients at clinic P. The primary 
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project aim was to improve the Tdap vaccination rates by adhering to ACOG’s recommendation 
of 100% Tdap vaccination for all pregnant women with each pregnancy.  
There was a need to reform current practices of the healthcare system at clinic P by 
implementing disciplined strategies to improve and implement the appropriate guidelines to 
protect the mother, baby, and community. Focusing on this issue was necessary to promote 
change and improve the quality of care to pregnant women. In accordance with ACOG 
guidelines, for Tdap immunization of pregnant women, the objectives of the intervention were: 
1. Establish a clinic protocol for Tdap vaccination: Implement standing orders for Tdap 
vaccination within the host health system.
2. Educate and train all clinic staff and healthcare providers: Provide training to 100% of 
staff and providers on clinical protocol and ACOG recommendations as applied within 
the protocol.
3. Educate all obstetrical patients on the importance of Tdap vaccination at 2 timepoints: 
Provide educational materials and information regarding the benefits of Tdap 
vaccinations to 100% of the prenatal patients at 2 separate timepoints during their 
pregnancy (at the initial prenatal appointment, and prior to vaccination at 27-36 weeks 
gestation).
4. Initiate provider recommendations for Tdap vaccinations: All staff providers will 
recommend the vaccination to 100% of their pregnant patients during an obstetrical 
appointment in which the woman is between 27 to 36 weeks gestation.
5. Administer Tdap vaccinations: Administer the Tdap vaccination to 100% of all pregnant 
women, with each pregnancy, between 27 to 36 weeks gestation.
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Summary and Strength of Evidence 
Based on the evidence surrounding the benefits of the Tdap vaccination, ACOG 
recommended in their September 2017 Committee Opinion (Number 718), that all pregnant 
women receive the Tdap vaccination in the third trimester of each pregnancy. Despite ACOG 
recommendations for vaccination of Tdap to pregnant women in their third trimester, and with 
each pregnancy, the CDC surveillance report (2017) from 2002 to 2012 indicated an increase of 
3,000 infant pertussis cases. To determine the available evidence related to Tdap vaccination in 
pregnancy and the passive immunity provided to the infant in utero, the following search terms 
“primary care,” “pregnant women,” “Tdap vaccinations,” “pertussis,” “passive immunity,” 
“vaccine,” “whooping cough,” “immunization,” and “maternal vaccination” guided the search 
for peer-reviewed articles written within the past 5 years.  
O’Halloran et al. (2016) found that the Tdap vaccination administered during each 
pregnancy within the third trimester (optimally between the 27-36 weeks gestation), promoted 
adequate protection of the unborn child through an increase in antibodies and passive immunity 
from the mother. Their study also emphasized the importance of OB/GYN providers 
recommending and educating pregnant women on the importance of the immunization with each 
pregnancy, along with the routine use of health care reminder systems to promote the 
recommendations at the optimal point in pregnancy. In relation to the mother’s passive 
immunity, Baxter et al. (2017) conducted a retrospective cohort study of infants between 2010 
and 2015, evaluating the efficiency of the Tdap vaccination during pregnancy to provide 
protection to the newborn against pertussis until the infant reaches the age where they may 
receive their first dose of DTap. They found that the maternal Tdap vaccination protected the 
infant against pertussis up until the infant’s first round of vaccinations. The findings also 
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validated the current ACOG recommendations for administering the Tdap vaccination with each 
pregnancy (Baxter et al., 2017).   
Regarding the education of pregnant women about the Tdap vaccination, Kriss et al. 
(2019) performed a national Internet panel survey and study of pregnant women in the US to 
obtain initial data that would inform the development of appropriate educational strategies and 
materials regarding the Tdap vaccination. The primary objectives of this study were to evaluate 
the self-reported status of pregnant women (vaccinated or unvaccinated) in the United States, and 
to determine whether these answers were affected by race, ethnicity, or other factors that could 
affect a pregnant woman’s ability to make an informed decision about receiving the Tdap 
vaccination (Kriss et al., 2019). The results of the study indicated that Hispanic women had 
higher Tdap vaccination rates than both white women and black women (53%, p < .05, 
compared with 38% and 36% respectively), and that both higher income and a geographical 
location within the western United States were also independently associated with Tdap 
vaccination during pregnancy (Kriss et al., 2019). The investigators further concluded that a 
health care provider’s Tdap recommendation was the most common factor influencing a 
pregnant woman’s decision and providing pregnant women with educational materials regarding 
the importance of the Tdap vaccination increases the likelihood of their receiving the Tdap 
vaccination (Kriss et al., 2019).  
Payakachat et al. (2015) conducted a randomized prospective study to test the 
effectiveness of the Tdap vaccine information statement (VIS) in encouraging pregnant women 
to receive the Tdap vaccination at two different clinics. The average age of the women at entry 
into the study was 26.4 years, and they were approximately 26 weeks gestation. Of this sample, 
only 13% of the selected women had received the Tdap vaccination prior to the survey. Notably, 
the mean gestational age of the sample would indicate that many of the women were not yet 
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eligible for vaccination, which may have affected the results. Despite this unclear method, the 
authors found that by providing the surveyed women with a Tdap VIS (a patient information 
document produced by the CDC), they could increase the overall perception of the Tdap vaccine 
during each pregnancy and increase vaccination rates (Payakachat et. al, 2015).  
There is a need for preventative screening in pregnant women and evidence-based 
methods to assist with prevention of pertussis. According to the ACOG recommendation, 100% 
of pregnant women should receive the Tdap vaccination to prevent pertussis and protect the lives 
of newborns. The CDC recommends that the VIS be given when a woman is notified of 
pregnancy, as well as before the administration of the Tdap vaccination to provide them with the 
information they need to make an informed decision regarding vaccination. Provider 
recommendations, patient educational materials, and professional development of health care 
providers and staff is essential for the uptake of maternal Tdap vaccination to provide passive 
immunity and protection to newborns against infection.  
Project Intervention 
The translation of evidence into practice requires a well thought out process that aligns to 
the needs of the healthcare team and their patient population. The evidence translation included 
these four steps outlined below.
Protocol Development and Training of Staff 
The first step was to establish a protocol that included the healthcare team providing each 
pregnant women with a VIS at the patient’s initial prenatal visit, and again at the recommended 
point of vaccination between 27 and 36 weeks gestation, so the mother is able to make an 
informed decision regarding the Tdap vaccination. Providing each patient with information 
about the vaccination with each pregnancy helps dispel some of the myths associated with  
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vaccinations, particularly during pregnancy. Each member of the healthcare team was 
encouraged to watch a special educational video regarding the importance of Tdap 
administration for pregnant women during the recommended gestational age. The video was 
short, lasting only 25-30 minutes, with content that aligned to the planned protocol and 
intervention. In addition, a survey regarding Tdap vaccination in pregnant women and providing 
education to the women within the clinic was given to all clinic staff. The survey, based on CDC 
guidelines, was 15 questions long, and the data obtained from the surveys was used to evaluate 
the staff’s knowledge and understanding of the importance of the Tdap vaccination to determine 
whether the educational videos improved or otherwise impacted the intervention.  
Education of Patients  
The intervention included educating the patient on the Tdap vaccination with the use of 
the VIS produced by the CDC. The VIS was to be provided to each patient at the first prenatal 
appointment and again at the appointment in which the provider recommends the vaccination. 
The VIS provides the patient with information regarding the benefits of Tdap vaccination with 
each pregnancy and the need for family members in contact with the newborn to also receive the 
vaccination.  
Recommendation From the Provider  
The study conducted by Payakachat et. al (2015) described the benefits of educating 
mothers on the Tdap vaccination, with an emphasis on the increased vaccination rates in women 
whose physician specifically described the vaccine during their prenatal visit. To this end, the 
obstetrical healthcare providers were encouraged to recommend the Tdap vaccination at a 
prenatal appointment between 27 and 36 weeks gestation and ensure that each woman received 
educational materials that describe the benefits of the vaccination during pregnancy. The 
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recommendation is facilitated by establishing a rapport with pregnant patients during their very 
first prenatal visit. This relationship promotes and improves the continuity of care. 
Vaccination Administration 
The primary aim of the intervention was the administration of the Tdap vaccination. Each 
step of the intervention focused on the promotion of vaccination uptake through patient 
education and provider recommendation. Key to the entire intervention was the Tdap 
vaccination recommendation given by the provider to the pregnant woman at 27 to 36 weeks 
gestation. The clinic staff were then prepared to administer the vaccination to 100% of the 
women receiving the recommendation and meeting the gestational age guidelines.  
The intervention was a quality improvement project that produced non-generalizable 
results. The evaluation of the intervention steps and outcomes was accomplished through chart 
reviews. The IRB review deemed the project to be non-regulated research/quality improvement. 
Evaluation Plan 
Project outcomes were collected throughout the intervention (February 3, 2020 – May 3, 
2020). The outcomes, directly aligned to the project objectives, were (a) the presence of standing 
orders on each patient’s chart for Tdap vaccination at 27 to 36 weeks gestation, (b) 
documentation within the patient record that the VIS was given at the initial prenatal 
appointment and again at an appointment between 27 to 36 weeks gestation, (c) a provider note 
indicating that Tdap vaccination was recommended at 27 to 36 weeks gestation, and (d) 
documentation of the Tdap vaccination being administered to patients between 27 to 36 weeks 
gestation or an indication as to why the vaccination was not administered within the patient 
record and NEXTGEN.   
 Each outcome variable was assessed for the percentage of change in protocol from the 
start of the intervention, and the results were compared to the clinic’s vaccination rate from 
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2019, when only 40% of over 300 obstetric patients received their Tdap vaccination. The 
overall aim of the project was to increase the immunization rates from 40% to 90%. This aim 
was based on the ACOG recommendation that 100% of women should receive the Tdap 
vaccination with each pregnancy.  
Results 
During February 3, 2020 to May 3, 2020, 338 women presented for prenatal care. The 
women were predominantly Hispanic (60.9%), were on average, 9 weeks pregnant at their first 
appointment, and most were pregnant with their first or second child (70%), at a mean age of 29 
years (Table 1).  
Table 1 
Summary of Demographic Characteristics 
Characteristic Total 
(n = 338) 
Age [Years, Mean (SD)] 28.76 (6.37) 
Husband’s Age [Years, Mean (SD)] 30.25 (5.79) 
Gestational Age [Weeks, Mean (SD)] 8.8 (4.23) 
Race/Ethnicity n(%) 
Hispanic 206 (60.9) 
White, Non-Hispanic 97 (28.7) 
Black, Non-Hispanic 17 (5) 
Others 13 (3.8) 
Parity n(%) 
0 126 (37.3) 
1 109 (32.2) 
2 84 (24.9) 
3 or more 19 (5.6) 
Provider/Patient Break-down n(%) 
MD_1 218 (64.5) 
MD_2 120 (35.5) 
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Implementing Protocol and Staff Education 
A standardized protocol was developed with standing orders for vaccinations between 
27 to 36 weeks. The clinic’s healthcare team ensured all patient records for patients being seen 
between 27 to 36 weeks were flagged. All of the clinic staff were prompted to view a short 
educational video (25-30 minutes) on the importance of the Tdap vaccination and the various 
misconceptions surrounding vaccinations in our current culture. They were then provided a 
survey with 15 questions to gauge their knowledge of the topic. Four staff members (one LVN 
and three MAs) completed the training and survey questions. There were eight yes-or-no 
questions and seven fill-in-the-blanks questions (Appendix B). The survey was given twice at the 
beginning of the project with an average score of 80%, and at the end of the project the scores 
were 100%.  
Patient Education 
All obstetrical patients received educational materials and information regarding the 
importance and benefits of the Tdap vaccination at their initial prenatal appointment and again at 
an appointment prior to their gestational window of 27-36 weeks when the provider 
recommended the vaccination. The VIS was provided to 100% of the obstetrical patients at both 
timepoints. 
Provider Vaccination Recommendation 
All patients received an initial verbal recommendation from their provider at their first 
prenatal encounter. Each patient recommendation was documented within the EMR. Later in the 
intervention, 190 of the 338 OB patients (60.5%) received a second provider recommendation as 
they reached the gestational window of 27-36 weeks. One hundred and thirty-one women 
(38.8%) did not receive a second provider recommendation as they were too early in their 
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pregnancy to receive the vaccination during the intervention period. Seven women (2.1%) were 
too far along in their pregnancy to receive a recommendation (or a vaccination) (Table 2). 
 Table 2 
Vaccination Administration 
One hundred and ninety women received Tdap vaccinations during the period of the 
intervention. Of the 207 vaccine-eligible women, 10 women (5%) declined the Tdap vaccine 
after being provided a recommendation from their provider and educational materials on the 
safety and benefits of the vaccination. There were no correlations with declining the vaccination 
to age, ethnicity, or parity. Ultimately, 190 of the total women in the sample (56.2%) were 
administered the Tdap vaccination between 27 and 36 weeks gestation (Table 3). 
 One hundred and thirty-one of the 338 OB patients (40.8%) initiating prenatal care during 
the intervention were not eligible for vaccination as they fell outside of the 27 to 36 week 
Tdap Recommendation 
Recommendation Week’s Gestation Total (n = 338) 
n(%) 
Initial prenatal visit 
2-12 weeks 292 (86.4) 
13-20 weeks 41 (12.1) 
> 21 weeks 5 (1.5) 
Prior to vaccination 
27-36 weeks 207 (100) 
Note: The numbers reflect all women who received prenatal care during the project 
period. Some women received the initial prenatal recommendation, but they are not able 
to receive the Tdap vaccination due to the window for vaccination of 27-36 weeks 
gestation. 
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gestational range per ACOG guidelines. Seven women (2.1%) were missed and did not 
receive a Tdap vaccination.  
Table 3 
Tdap Vaccinations 
Vaccination Stats Week’s 
Gestation 
         Total (n = 338) 
n(%) 
Vaccination received 
27-36 weeks 190 (56) 
Vaccination not received 
<27 weeks 131 (39) 
Declined 10 (3) 
Missed 7 (2) 
Note: The numbers reflect all women who entered prenatal care during the project 
period. Some women received the initial prenatal recommendation, but they are not yet 
able to receive the Tdap vaccination due to the window for vaccination of 27-36 weeks 
gestation.  
Discussion 
This quality improvement project sought to implement a Tdap vaccination program and 
increase the rates of vaccinations of obstetrical patients at a San Antonio, Texas, clinic. The 
intervention included developing a clinic protocol and staff training, patient education, and 
instructions for provider recommendation, and resulted in 100% of OB patients receiving 
education and recommendations for the Tdap vaccination, as well as an overall increase in 
Tdap vaccination rates so that 190 of 207 vaccine-eligible women (95%) were administered the 
vaccination.  
The clinic’s current electronic medical record does not include a flag system to alert 
providers that OB patients are within the 27 to 36 weeks gestational window to receive the 
Tdap vaccination. Therefore, the MAs manually updated the daily brief (a run-down of each 
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patient appointment) the day before a patient’s visit. Seven prenatal patients (2.1%) received the 
initial patient Tdap educational materials and an initial recommendation from their provider at 
their first prenatal visit, but they did not receive the Tdap vaccine during the recommended 
gestational age, prior to giving birth. It is possible that these seven women were overlooked due 
to human or system error and therefore did not receive the recommendation or the vaccination 
prior to delivery. Though the intervention step involving the implementation of the clinic 
protocol generally produced positive results (there was an increase of ~16.2% in Tdap 
vaccination rates), a better flag system is necessary for the clinic to achieve the ACOG 
recommendations of 100% of vaccine-eligible patients receiving the vaccine.  
Prior to the intervention, the clinic staff were utilizing evidence-based best practices like 
referring to the VIS and the CDC guidelines. However, the staff were not providing the VIS to 
every pregnant patient with each initial prenatal visit, a necessary step for increasing the 
mother’s opportunity to make an informed decision regarding the Tdap vaccination with each of 
her pregnancies.  
All 338 women in the sample were given the initial verbal recommendation from the 
provider at their first OB appointment, and they were given the VIS within their prenatal 
orientation packet. The vast majority of the OB patients accessed early prenatal care as reflected 
in the mean gestational age at first prenatal appointment in our sample. All Tdap vaccinations 
were appropriately documented within NEXTGEN. Patients’ refusals to receive the vaccine (10 
of the 207 (5%) vaccine-eligible women) affected the overall goal of reaching a 100% 
vaccination rate for vaccine-eligible patients.  
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Limitations 
The absence of a flagging system within the electronic medical record for the gestational 
age and need for vaccination, was an intervention limitation. The absence of a vaccine-alert 
increased the MAs workload and accountability for ensuring that the daily patient brief included 
this notification. Additionally, a task box for documentation of the provider recommendation of 
Tdap vaccination was not included in NEXTGEN. This created an added responsibility for the 
provider to manually document Tdap recommendations within the patient encounter note. The 
lack of task boxes and flagging systems placed an additional burden on the staff who were then 
responsible for looking within the providers’ documentation to see if (a) educational materials 
and provider recommendations were given to the patient, and (b) whether the patient’s chart was 
flagged for being within the recommended gestational window for the vaccination. 
During the clinic assessment, the MAs conveyed that they were overwhelmed with the 
current workload and adding any additional tasks to their day was a concern. Initially, there was 
excitement by the staff and providers for the intervention, given the benefits to both mother and 
infant. However, midway through the implementation, the COVID-19 pandemic dramatically 
effected clinical operations. The OB/GYN providers began practicing out of one clinic that 
provided services for only OB/GYN patients. Therefore, the clinic staffing ratios changed and 
only one MA was sent to work with both providers. The MA was able to integrate the 
intervention tasks into her routine, but without the added assistance of the other two MAs she 
was solely responsible for flagging the daily brief, providing the education materials, and 
administering the vaccinations. The providers were committed to the intervention and all steps 
were maintained despite the COVID modifications in patient appointments. Nevertheless, seven 
patients that were eligible did not receive the vaccine. 
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Recommendations 
Initiating discussions about the Tdap vaccination with OB patients should begin prior to 
the recommended gestational window, typically within the first prenatal visit. There were 
approximately 207 women who were eligible for the Tdap vaccination between February 3, 
2020 and May 3, 2020, and 190 women were administered the vaccination. 
Sustainment of the intervention and possible modifications could address the issues for 
the vaccine-eligible women choosing not to receive the vaccination, despite receiving both 
provider recommendations and education. Suggestions for addressing these women’s’ concerns 
or hesitation could involve developing clearer educational materials, confronting financial 
barriers, or even assisting women in accessing transportation services to attend prenatal 
appointments. 
Alerts systems within the EMR and standing orders for vaccination are recommended to 
alert the staff when administration is due. Task boxes added within the EMR would streamline 
documentation and improve provider/staff participation in the intervention. These additions 
within the EMR would promote evaluation of adherence to the protocol and reduce the number 
of patients that missed the window to receive Tdap. 
Implications for Practice 
This evidence-based practice project increased awareness of the importance of the Tdap 
vaccination for all pregnant women. It provided the entire clinic staff with an opportunity to 
implement an evidence-based practice change. ACOG recommendations and CDC guidelines 
were used to guide the project. The clinic assessment revealed practices that prevented the 
identification of OB patients within the recommended gestational window, and therefore 
prevented vaccine-eligible women from receiving the Tdap vaccination as recommended. By 
addressing this issue, in addition to developing patient and staff educational materials and a 
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clinic protocol, prenatal Tdap vaccination rates at the host clinic increased, which will ultimately 
improve health outcomes (Abraham et al. 2018). 
 The host clinic accepted the evidence-based practice changes to the prenatal 
immunization protocol/process. Piloting of the intervention identified that the agreed-upon 
process changes could be easily integrated and sustained within the host clinic. 
Summary 
Establishing a strong relationship with an OB/GYN provider for preventative and early 
comprehensive prenatal care can lead to improved quality of care. Many women are unaware of 
the importance of prenatal immunizations and the benefits for both themselves and for their 
unborn child. The combination of implementing clinic protocols and educating staff on these 
protocols, educating patients on the importance of vaccinations, and provider recommendations 
all contributed to increased rates of prenatal vaccinations. Prenatal visits become vital 
opportunities for recommending, educating, and administering vaccinations. 
This prenatal immunization program intervention improved access to general medical 
education and immunization awareness for pregnant women. The intervention, based on ACOG 
recommendations and CDC guidelines, were found to be effective within this project and can be 
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Appendix A 
Letter of Support 
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Appendix B 
Survey Questionnaire 
Survey Questionnaire: Tdap Vaccine during Pregnancy  
1. Have you heard of the Tdap vaccine before today? ____Yes or ____No
2. Does the healthcare provider recommend the Tdap vaccine during pregnancy? _____Yes
or _____No 
3. What does the Tdap vaccine prevent? ____________
4. What is the recommended gestational age do the pregnant patient receive the Tdap
vaccine? ________ 
5. Do you administer the Tdap vaccine after 36 weeks of gestation? _____Yes or ____ No
6. Do pregnant women receive the Tdap vaccine with each pregnancy? ____Yes or ____No
7. How does the Tdap Vaccine help the baby? ____________________
8. At what age can the baby receive their first vaccines? _________
9. Is the Tdap vaccine harmful to the fetus? ______Yes or _______No
10. Is the Tdap vaccine harmful to the mother during pregnancy? _____Yes or _____No
11. When do you provide educational material to the pregnant patient about the Tdap
vaccine? __________________ 
12. What is the name of the educational material given to the pregnant patient?
______________________ 
13. On what website can you find the vaccination information sheet (VIS)? ________
14. Do the family or close contacts get the Tdap vaccine prior to the baby’s birth? ________
Yes or ________ No 
15. Is the Tdap vaccine covered by most insurances? _____ Yes or _____No
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Appendix C 
Vaccine Information Statement 
Retrieved from the CDC at https://www.cdc.gov/vaccines/hcp/vis/vis-statements/tdap.pdf. 
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Appendix D 
List of Educational Videos for Staff Training 
Centers for Disease Control and Prevention (CDC). (2019, May 9). Dr. Pamela Rockwell’s Flue 
and Tdap Vaccine Recommendation to Pregnant Patients [Video]. YouTube. 
https://www.youtube.com/watch?v=USf7nLybajg 
Centers for Disease Control and Prevention (CDC). (2019, May 9). Nurse-Midwife Carol Hayes 
on Improving Practices’ Maternal Vaccination Rates [Video]. YouTube. 
https://www.youtube.com/watch?v=DG-1Yfeq0BI 
Centers for Disease Control and Prevention (CDC). (2019, May 9). Nurse-Midwife Carol Hayes 
on Tdap Vaccine: Importance and Recommendations [Video]. YouTube. 
https://www.youtube.com/watch?v=jiIuqap4eQs 
Centers for Disease Control and Prevention (CDC). (2016, Jan. 12). Pregnant? Help Protect 
Your Baby from Whooping Cough [Video]. YouTube. 
https://www.youtube.com/watch?v=SkafS5pwMuo 
U.S. Department of Health and Human Services. (2018, July 31). Your Best Shot – Whooping 
Cough Vaccines [Video]. YouTube. https://www.youtube.com/watch?v=AC58by5_iqo 
